Dr. Reddy’s Laboratories, a prominent player in the pharmaceutical sector, has made a significant move by acquiring trademarks and related assets for two specialty brands, Progynova and Cyclo-Progynova, from the U.K.-based Mercury Pharma Group. This acquisition, announced on February 18, 2026, marks a pivotal step for Dr. Reddy’s as it ventures into the hormone replacement therapy (HRT) market in India.
Strengthening the Gynaecology Portfolio
The acquisition of Progynova and Cyclo-Progynova enhances Dr. Reddy’s existing gynaecology offerings. Progynova, which contains estradiol valerate, is primarily used for treating symptoms of estrogen deficiency and for preventing postmenopausal osteoporosis. On the other hand, Cyclo-Progynova combines estradiol valerate with norgestrel, addressing estrogen deficiency symptoms with both estrogen and progestogen components.
Market Leadership and Brand Recognition
Progynova is not just any other medication; it holds the title of the leading brand in the Estradiol segment within the Indian market. With a robust presence among healthcare professionals and a strong brand recall, Progynova generated impressive sales of ₹100 crore, as reported with figures from IQVIA for the period ending December 2025.
Strategic Expansion into HRT
M.V. Ramana, the CEO of Branded Markets for India and Emerging Markets at Dr. Reddy’s, emphasized that this acquisition represents a strategic initiative to bolster the company’s foothold in the HRT sector. By adding these brands to its portfolio, Dr. Reddy’s aims to enhance its gynaecology segment and cater to the growing demand for hormone replacement therapies in India.
Implications for Women’s Health
The entry into the HRT market is timely, considering the increasing awareness and need for effective treatment options for women experiencing menopause and related health issues. By providing established brands like Progynova and Cyclo-Progynova, Dr. Reddy’s can contribute to improving the quality of life for women facing estrogen deficiency.
Future Prospects
As Dr. Reddy’s Laboratories integrates these brands into its operations, the company is poised to leverage its extensive distribution network and marketing capabilities to maximize the potential of these products. The acquisition not only signifies growth for the company but also aligns with its mission to enhance healthcare offerings in India.
Conclusion
Dr. Reddy’s Laboratories is strategically positioning itself within the hormone replacement therapy market through the acquisition of Progynova and Cyclo-Progynova. This move not only strengthens its gynaecology portfolio but also addresses an essential aspect of women’s health. As the company embarks on this new chapter, it promises to deliver impactful solutions for those seeking hormonal balance.
- Key Takeaways:
- Dr. Reddy’s acquires Progynova and Cyclo-Progynova to enter the HRT market.
- Progynova is the leading brand in the Estradiol segment in India.
- The move aims to enhance the company’s gynaecology portfolio and address women’s health needs.
- M.V. Ramana highlights strategic expansion into a growing market segment.
- The acquisition is a response to rising demand for effective HRT solutions.
Read more → www.thehindu.com